9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      809
      Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia

      abstract

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background.  Community-acquired bacterial pneumonia (CABP) is a serious infection in many patients. Ceftaroline fosamil (CPT-F) is approved for the treatment of CABP and acute bacterial skin and skin structure infections in the US, and for similar indications in the EU. CAPTURE is a multicenter registry study describing patients treated with CPT-F in the US. Methods.  Data were collected at participating centers by randomly ordered chart review between September 2011 and February 2014, which included demographics, disease characteristics, antibiotic use, location of care, and clinical response. Evaluable patients (pts) were those with a clinical outcome determined. Results.  649 pts were evaluable. Demographics and co-morbidities are presented in the table. On diagnosis 81% of pts had 2 or more signs and symptoms; most common were dyspnea (76%), cough (65%), abnormal auscultatory findings (63%), and sputum production (46%). At initiation of CPT-F treatment, 35% were located in an intensive care unit (ICU). 84% received prior antibiotics; most commonly ceftriaxone (35%), vancomycin (31%), azithromycin (27%) and levofloxacin (26%). The mean duration of CPT-F therapy was 6.1 days (SD ± 3.8). Concurrent antibiotics were used in 64% and included azithromycin (23%), levofloxacin (17%) and vancomycin (8%). Overall clinical success was 83%; 73% in the ICU and 88% in the ward. Clinical success with CPT-F monotherapy was 84%, and with concurrent therapy, 83%. Clinical success was 85% for CPT-F as first line therapy and 83% as 2nd line therapy. CPT-F was discontinued in 8 (1%) pts due to an adverse event. The majority of pts were discharged to home (60%) or to another healthcare facility (35%). Demographics and Co-morbidities Pts (N=649) n (%) Males, Females 315 (49)334 (51) Age, years, mean (SD), range 63.4 (17.5)18–99 Pts with co-morbidities 514 (79) Structural lung disease 276 (43) Smoking 223 (34) Gastroesophageal reflux 146 (22) Prior pneumonia 159 (24) Congestive heart failure 134 (21) Cerebrovascular accident 53 (8) Alcoholism 54 (8) Conclusion.  Contemporary clinical use of CPT-F for treating CABP show high rates of clinical success including pts in the ICU. CAPTURE data support the use of CPT-F as an important antibiotic for treatment of complicated CABP. Disclosures.   L. B. Johnson, Forest Laboratories: Investigator, Research support C. M. Cannon, Forest Laboratories: Investigator and Speaker's Bureau, Research support and Speaker honorarium L. E. Johnson, Forest Laboratories: Investigator, Research support S. Wallace, Forest Laboratories: Shareholder, have owned approximately $25,000 in stock in Forest Laboratories, purchased long before any involvement with this project A. Jandourek, Cerexa Inc.: Employee, Salary H. D. Friedland, Forest Laboratories: Employee and Shareholder, Salary

          Related collections

          Author and article information

          Journal
          Open Forum Infect Dis
          Open Forum Infect Dis
          ofid
          ofids
          Open Forum Infectious Diseases
          Oxford University Press
          2328-8957
          December 2014
          December 2014
          : 1
          : Suppl 1 , IDWeek 2014 Abstracts
          : S230
          Affiliations
          [1 ]St. John Hospital and Medical Center/Wayne State University, Detroit, MI
          [2 ]University of Kansas Hospital, Kansas City, KS
          [3 ]Henry Ford Hospital, Detroit, MI
          [4 ]Good Samaritan Hospital, Los Angeles, CA
          [5 ]Cerexa, Inc., Oakland, CA
          Author notes

          Session: 106. Clinical Respiratory Infections

          Friday, October 10, 2014: 12:30 PM

          Article
          ofu052
          10.1093/ofid/ofu052.517
          5781575
          5d901d28-0b48-4534-9bb3-a83edc4dbee2
          © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America
          History
          Categories
          IDWeek 2014 Abstracts
          Poster Abstracts

          Comments

          Comment on this article